|Dr. Lishan Aklog M.D.||Chairman & CEO||N/A||N/A||1966|
|Mr. Dennis M. McGrath CPA||CFO, Pres & Sec.||N/A||N/A||1957|
|Dr. Sanford D. Markowitz M.D., Ph.D.||Cofounder & Strategic Advisor, Member of the Medical Advisor Board||14.54k||N/A||N/A|
|Dr. Joseph Willis M.D.||Cofounder, Strategic Advisor & Member of Medical Advisory Board||N/A||N/A||N/A|
|Dr. Amitabh Chak M.D.||Cofounder, Strategic Advisor & Member of Medical Advisory Board||N/A||N/A||N/A|
|Mr. Shaun M. O'Neill M.B.A.||Exec. VP & COO||N/A||N/A||1982|
|Richard D. Yazbeck||Chief Technology Officer||N/A||N/A||N/A|
|Dr. Suman M. Verma M.D., Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
|Mr. Adrian K. Miller||VP of Investor Relations||N/A||N/A||N/A|
|Dr. Brian J. deGuzman M.D.||Chief Compliance Officer||N/A||N/A||1965|
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Lucid Diagnostics Inc.’s ISS Governance QualityScore as of January 28, 2023 is 10. The pillar scores are Audit: 9; Board: 10; Shareholder Rights: 6; Compensation: 10.